You are here: Industry Insights > VIP

News List

NRx and MannKind to develop Zyesami inhaler for respiratory ailments pharmaceutical-technology
August 05, 2021
NRx Pharmaceuticals has entered an agreement with MannKind to create a dry powder formulation of its investigational drug, Zyesami (aviptadil), for the treatment of various respiratory ailments.
NRx Pharmaceuticals’ Zyesami yields positive data in EAP for Covid-19 pharmaceutical-technology
June 17, 2021
NRx Pharmaceuticals has reported positive results from the expanded access protocol (EAP) of its Zyesami (Aviptadil) in critical Covid-19 patients admitted to the ICU with respiratory failure.
NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure prnewswire
March 29, 2021
NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™ (aviptadil acetate) for the treatment of critically-ill patients with COVID-19 ...